Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Construction in Progress: 2011-2024

  • Heron Therapeutics' Construction in Progress fell 58.73% to $2.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.6 million, marking a year-over-year decrease of 58.73%. This contributed to the annual value of $2.6 million for FY2024, which is 58.73% down from last year.
  • Per Heron Therapeutics' latest filing, its Construction in Progress stood at $2.6 million for Q4 2024, which was down 58.73% from $6.3 million recorded in Q4 2023.
  • In the past 5 years, Heron Therapeutics' Construction in Progress ranged from a high of $15.9 million in Q4 2021 and a low of $2.6 million during Q4 2024.
  • Over the past 3 years, Heron Therapeutics' median Construction in Progress value was $5.4 million (recorded in 2022), while the average stood at $4.8 million.
  • As far as peak fluctuations go, Heron Therapeutics' Construction in Progress tumbled by 66.04% in 2022, and later climbed by 16.67% in 2023.
  • Heron Therapeutics' Construction in Progress (Quarterly) stood at $14.1 million in 2020, then grew by 12.77% to $15.9 million in 2021, then crashed by 66.04% to $5.4 million in 2022, then increased by 16.67% to $6.3 million in 2023, then crashed by 58.73% to $2.6 million in 2024.
  • Its last three reported values are $2.6 million in Q4 2024, $6.3 million for Q4 2023, and $5.4 million during Q4 2022.